BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says

 
• By Sue Sutter
ALS On Chalkboard
The ALS patient community is eager for new treatments. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards